Form 4: PTC Therapeutics Executive Stock Sale

Mark Elliott Boulding, Executive VP and CLO of PTC Therapeutics, exercised stock options and sold shares under a Rule 10b5-1 plan.

Summary

• Mark Elliott Boulding exercised options for 3,540 shares of PTC Therapeutics common stock at an exercise price of $46.54.
• Following the exercise, the reporting person sold a total of 3,540 shares in multiple transactions.
• The sales were executed at weighted average prices ranging from $78.00 to $79.31 per share.
• The transactions were conducted pursuant to a pre-established Rule 10b5-1 trading plan adopted on September 10, 2025.
• The reporting person retains beneficial ownership of 105,212 shares of common stock following these transactions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions were pre-planned and represent routine portfolio management by an executive.

Positives

• The transactions were executed under a pre-planned Rule 10b5-1 program, indicating the sales were not based on sudden non-public information.
• The executive continues to hold a significant position of 105,212 shares, maintaining alignment with shareholder interests.

Negatives

• The executive reduced their total direct holdings by 3,540 shares through the exercise and subsequent sale.

Risks

• Future share price volatility could impact the value of the remaining 105,212 shares held by the executive.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that executive stock sales under 10b5-1 plans are standard corporate practice for liquidity and diversification, and generally do not signal a change in company fundamentals.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate insiders to sell shares while avoiding potential insider trading liability.
• The volume of shares sold represents a small fraction of the executive's total holdings, which is consistent with typical executive compensation and liquidity management.

Stakeholder Impact

• Minimal impact on shareholders as the sales were conducted via a pre-arranged plan.

Next Steps

• The reporting person will continue to hold the remaining 105,212 shares of common stock.

Key Dates

Keywords

PTCT, PTC Therapeutics, Insider Trading, Form 4, Stock Options, Rule 10b5-1